Elevated plasma total homocysteine is associated with increased risk of
dementia/Alzheimer's disease, but underlying pathophysiological mechanisms are not fully …

A substantial body of evidence supports the hypothesis of a vascular component in the
pathogenesis of Alzheimer's disease (AD). Cerebral hypoperfusion and blood-brain barrier …

Background Insulin resistance (IR) and type 2 diabetes have been found to increase the risk
for Alzheimer's clinical syndrome in epidemiologic studies but have not been associated …

Advanced glycation end-product (AGE) is the generic term for a heterogeneous group of
derivatives arising from a non-enzymatic reaction between reducing sugars and proteins. In …

Given current lack of therapies for dementia, there is substantial interest in identifying
potentially modifiable risk factors. Clarifying the potential of these factors to mitigate risk as …

Background: Type 2 diabetes (T2D) is a risk factor for cognitive dysfunction. The relationship
between metformin therapy and cognitive function in patients with T2D is unknown …

In recent years, there is a growing interest in research to investigate the importance of gut
microbiome in health and diseases. This opens a new area of research for the role of …

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering
from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or …

The population of oldest old, or people aged 85 and older, is growing rapidly. A better
understanding of dementia in this population is thus of increasing national and global …

Alzheimer's disease (AD) is the most common cause of dementia, affecting more than 36
million people worldwide. AD is characterized by a progressive loss of cognitive functions …